阿尔法-酶通过MAPK/ERK信号通路促进急性髓性白血病的进展
Shanshan Zhang1,2, Haina Wang1,3, Xuehong Zhang4
1Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, the Second Hospital of Dalian Medical University, Dalian 116027, China.
Blood science (Baltimore, Md.)
|August 12, 2025
概括
阿尔法-酶 (ENO1) 在急性髓性白血病 (AML) 中过度表达,并与预后不佳有关. 针对ENO1可能为AML患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 耐药性和复发性急性髓性白血病 (AML) 存在重大治疗挑战,因为有效疗法有限.
- 确定新的治疗点对于改善AML患者的治疗结果至关重要.
研究的目的:
- 为了研究α-enolase (ENO1) 作为急性髓性白血病 (AML) 的潜在治疗点的作用.
- 确定ENO1在AML中的预后意义和功能影响.
主要方法:
- 在AML患者样本中对ENO1表达的定量分析.
- 试验室研究涉及AML细胞系中的ENO1淘汰 (shENO1),以评估对增殖,入侵和细胞周期的影响.
- 在体内研究,使用与U937-shENO1细胞植入的小鼠模型来评估治疗疗效.
主要成果:
- 发现α-enolase (ENO1) 在AML中显著过度表达,并与预后不佳相关.
- 在ENO1 knockdown中抑制了AML细胞的扩散和入侵,并在体外诱导细胞循环停止.
- 在体内,U937-shENO1异种移植与对照U937异种移植相比,显示了延长的生存期.
- 机理学研究表明,ENO1激活了基因激活蛋白激酶/细胞外信号调节激酶 (MAPK/ERK) 途径.
结论:
- ENO1是急性髓性白血病的一个有前途的治疗点.
- 向ENO1可能会改善AML患者的治疗策略和治疗结果.
相关概念视频
MAPK Signaling Cascades
6.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K
Amplifying Signals via Enzymatic Cascade
8.7K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.7K
Enzyme-linked Receptors
80.0K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
80.0K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K


